[Influence of interleukin-1beta genetic polymorphism on H. pylori eradication therapy].
Take
Susumu
S
Department of Internal Medicine, Fukuwatari Municipal Hospital.
Mizuno
Motowo
M
Ishiki
Kuniharu
K
D000658:Amoxicillin / Q000009:adverse effects; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D017291:Clarithromycin / Q000009:adverse effects; D004791:Enzyme Inhibitors / Q000009:adverse effects; D005744:Gastric Acid / Q000378:metabolism; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D007375:Interleukin-1 / Q000235:genetics* / Q000502:physiology; D011110:Polymorphism, Genetic; D054328:Proton Pump Inhibitors; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D004791:Enzyme Inhibitors; D007375:Interleukin-1; D054328:Proton Pump Inhibitors; D000658:Amoxicillin; D017291:Clarithromycin